Literature DB >> 11337190

Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital.

J W Baddley1, A M Smith, S A Moser, P G Pappas.   

Abstract

The frequency of isolation and antifungal susceptibility patterns to fluconazole and itraconazole were determined for 166 Candida glabrata isolates causing bloodstream infection at a single institution from 1995-2000. Findings demonstrated a trend of increasing resistance to itraconazole among the isolates, but no trend in resistance to fluconazole. The frequency of C. glabrata isolates among all blood culture isolates of Candida spp. causing bloodstream infection remained stable during the study period and ranged from 18-31%.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11337190     DOI： 10.1016/s0732-8893(01)00214-0

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  10 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

Authors:  Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin
Journal:  Curr Drug Metab       Date:  2013-02       Impact factor: 3.731

3.  Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice.

Authors:  Justina Y Ju; Cynthia Polhamus; Kieren A Marr; Steven M Holland; John E Bennett
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Barbara Fiori; Stefania Ranno; Riccardo Torelli; Giovanni Fadda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Relationships between respiration and susceptibility to azole antifungals in Candida glabrata.

Authors:  Sophie Brun; Christophe Aubry; Osana Lima; Robert Filmon; Thierry Bergès; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

6.  Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.

Authors:  Ingi Lee; Neil O Fishman; Theoklis E Zaoutis; Knashawn H Morales; Mark G Weiner; Marie Synnestvedt; Irving Nachamkin; Ebbing Lautenbach
Journal:  Arch Intern Med       Date:  2009-02-23

7.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

8.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Authors:  M A Pfaller; S A Messer; R J Hollis; L Boyken; S Tendolkar; J Kroeger; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

9.  Identification of Candida glabrata by a 30-second trehalase test.

Authors:  A-M Freydière; F Parant; F Noel-Baron; M Crepy; A Treny; H Raberin; A Davidson; F C Odds
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links.

Authors:  Boualem Sendid; Angélique Cotteau; Nadine François; Annie D'Haveloose; Annie Standaert; Daniel Camus; Daniel Poulain
Journal:  BMC Infect Dis       Date:  2006-05-02       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.